The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Patients with type 2 diabetes demonstrated improved glycemic control with the use of automated insulin delivery regardless of baseline C-peptide levels. Automated insulin delivery (AID) systems should ...

This video shows the complete oil change and oil level sensor replacement on the BMW E39 M5. We go step by step through the ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...

What if your surveillance system could do more than just watch? Imagine cameras so advanced they not only capture every detail in stunning 4K resolution but also intelligently analyze their ...

Tip-off: Monday, Nov. 3, 8:00 p.m. EST TV/Streaming: ESPN+ (Play-by-Play: Austin Lyon, Analyst: Mike O'Donnell) Radio: FM 96.9 FM / AM 740 (Play-by-Play: Marc Daniels, Analyst: Taylor Young) Live ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...